CN1183935C - Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases - Google Patents
Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases Download PDFInfo
- Publication number
- CN1183935C CN1183935C CNB021137978A CN02113797A CN1183935C CN 1183935 C CN1183935 C CN 1183935C CN B021137978 A CNB021137978 A CN B021137978A CN 02113797 A CN02113797 A CN 02113797A CN 1183935 C CN1183935 C CN 1183935C
- Authority
- CN
- China
- Prior art keywords
- monacus
- monascus
- notoginseng
- composition
- red rice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 38
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 235000007189 Oryza longistaminata Nutrition 0.000 title abstract description 10
- 240000007594 Oryza sativa Species 0.000 title abstract description 10
- 235000007164 Oryza sativa Nutrition 0.000 title abstract description 10
- 230000000747 cardiac effect Effects 0.000 title description 2
- 230000002490 cerebral effect Effects 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 20
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 19
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 235000013373 food additive Nutrition 0.000 claims abstract description 4
- 239000002778 food additive Substances 0.000 claims abstract description 4
- 244000113306 Monascus purpureus Species 0.000 claims description 29
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 29
- 229940057059 monascus purpureus Drugs 0.000 claims description 29
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004040 coloring Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 claims description 2
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 claims description 2
- 244000038561 Modiola caroliniana Species 0.000 claims description 2
- 235000010703 Modiola caroliniana Nutrition 0.000 claims description 2
- 241000235395 Mucor Species 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000007901 soft capsule Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 11
- 229960004844 lovastatin Drugs 0.000 description 11
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000008802 xuezhikang Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021137978A CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021137978A CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1383871A CN1383871A (en) | 2002-12-11 |
CN1183935C true CN1183935C (en) | 2005-01-12 |
Family
ID=4742812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021137978A Expired - Lifetime CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1183935C (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
CN103251042A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
CN102599501B (en) * | 2012-03-15 | 2013-11-06 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
CN103655697A (en) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | Product for reducing blood fat and preparation process thereof |
CN103493681A (en) * | 2013-09-24 | 2014-01-08 | 成都信息工程学院 | Method for producing medical mycoplasm by using pseudo-ginseng dregs in co-fermentation mode |
CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
-
2002
- 2002-05-27 CN CNB021137978A patent/CN1183935C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1383871A (en) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100336517C (en) | Red rice and gingko leaf composition for preventing and treating cardiovascular and cerebrovascular disease and its application | |
CN1259935C (en) | Medicine for treating hyperlipemia | |
CN104667283B (en) | A kind of compound medicine combination for treating dyslipidemia and atherosclerosis | |
CN1183935C (en) | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases | |
EP2938350B1 (en) | Medical formulation for treating hypercholesterolemia | |
CN1173707C (en) | Medicinal composition containing baicalin and caffoeoylchinic acid | |
CN101961492A (en) | Ezetimibe compound preparation for treating dyslipidemia | |
CN1213747C (en) | Specific therapeutic composition for treating AIDS | |
CN105641509A (en) | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application | |
CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
Barylski | Monakolina i atorwastatyna w prewencji zdarzeń sercowo-naczyniowych-próba pozycjonowania | |
CN101062097A (en) | Compound for improving and treating fatty liver disease | |
CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
CN1660352A (en) | Combination of medication of possessing synergetic effect | |
KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
CN1195537C (en) | External-applied Chinese medicine for treating hypertension and its preparing process | |
CN102283831B (en) | Western medicine compound for curing coronary diseases and application | |
CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
CN1461656A (en) | Medicinal excipient-potassium alginate and its composition | |
CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
CN112999216B (en) | A pharmaceutical composition containing tylosin for treating diabetic cardiomyopathy | |
CN102161619B (en) | Ferulic acid Jiangtang compound salt as well as preparation method and application thereof | |
CN101856403B (en) | Medicinal composition, preparation method thereof and pharmaceutical application | |
CN1762440A (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
CN104434920B (en) | A kind of pharmaceutical composition treating heart failure and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YUNDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YUNDA SCIENCE +. TECHNOLOGY CO., LTD. Effective date: 20071026 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071026 Address after: 100021 Beijing city Chaoyang District East sanhuan Road No. 21 Yijingjiayuan No. 1 building 10 room G Patentee after: Beijing Yunda Pharmaceutical Co. Ltd. Address before: 650106 No. 59, medical Road, hi tech Industrial Development Zone, Yunnan, Kunming Patentee before: Yunda Science &. Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: MENG QINGFA Free format text: FORMER OWNER: BEIJING YUEDA PHARMACEUTICAL CO., LTD. Effective date: 20141209 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100021 CHAOYANG, BEIJING TO: 518100 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141209 Address after: 518100 Dragon Pavilion 12E, dragon pearl garden, Buji Town, Longgang District, Guangdong, Shenzhen Patentee after: Meng Qingfa Address before: 100021 Beijing city Chaoyang District East sanhuan Road No. 21 Yijingjiayuan No. 1 building 10 room G Patentee before: Beijing Yunda Pharmaceutical Co. Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20050112 |
|
CX01 | Expiry of patent term |